Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lexicon Pharmaceuticals provides first description of early development of LX-4211

March 30, 2012

DSMB recommends continuation of Menerba study

March 29, 2012

NGM and Daiichi Sankyo to collaborate on novel diabetes therapies

March 29, 2012

FDA responds to SPA for phase III elagolix trial

March 28, 2012

New diacylglycerol O-acyltransferase 1 inhibitors show promise to treat metabolic diseases

March 28, 2012

Novel 2-spiro-proline derivative inhibits 11-beta-HSD1

March 28, 2012

EMA accepts lorcaserin MAA for review

March 27, 2012

Merck & Co. selects new agent for development in diabetes

March 27, 2012

ScinoPharm and NHRI to begin phase I trial of DBPR-108

March 27, 2012

EMA validates Raptor's MAA for RP-103

March 26, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...